Hormone Replacement Therapy in Postmenopausal Women with Diabetes Mellitus

 

 Buy Article Permissions and Reprints

ABSTRACT

Postmenopausal women with type 2 diabetes mellitus have a high risk of cardiovascular disease. Hormone replacement therapy (HRT) with estrogens with or without progestagens relieves many climacteric symptoms. Although hormone replacement in theory could have beneficial effects on cardiovascular morbidity, to date no randomized controlled clinical trial has shown positive results in this regard. There are few data with respect to diabetic postmenopausal women.

There is no basis for prescription of HRT to diabetic women if the aim is to lower cardiovascular morbidity. On the other hand, there is also no reason not to prescribe HRT to diabetic women to treat climacteric symptoms.

REFERENCES

• 1 Coope J, Thomson J M, Poller L. Effects of ``natural oestrogen'' replacement therapy on menopausal symptoms and blood clotting.  BMJ . 1975;  4 139-143
  PubMedGoogle Scholar
• 2 Rosing J, Middeldorp S, Curvers J. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.  Lancet . 1999;  354 2036-2040
  CrossrefPubMedGoogle Scholar
• 3 Oleksik A M, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.  J Clin Endocrinol Metab . 2001;  86 2763-2768
  CrossrefPubMedGoogle Scholar
• 4 Nicodemus K K, Folsom A R. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.  Diabetes Care . 2001;  24 1192-1197
  CrossrefPubMedGoogle Scholar
• 5 Barrett-Connor E, Bush T L. Estrogen and coronary heart disease in women.  JAMA . 1991;  265 1861-1867
  CrossrefPubMedGoogle Scholar
• 6 Grady D, Rubin S M, Petitti D B. Hormone therapy to prevent disease and prolong life in postmenopausal women.  Ann Intern Med . 1992;  117 1016-1037
  PubMedGoogle Scholar
• 7 Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group.  JAMA . 1998;  280 605-613
  CrossrefPubMedGoogle Scholar
• 8 Herrington D M, Reboussin D M, Brosnihan K B. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.  N Engl J Med . 2000;  343 522-529
  CrossrefPubMedGoogle Scholar
• 9 Viscoli C M, Brass L M, Kernan W N, Sarrel P M, Suissa S, Horwitz R I. A clinical trial of estrogen-replacement therapy after ischemic stroke.  N Engl J Med . 2001;  345 1243-1249
  CrossrefPubMedGoogle Scholar
• 10 Mosca L, Collins P, Herrington D M. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.  Circulation . 2001;  104 499-503
  PubMedGoogle Scholar
• 11 Dunne F P. Should women with diabetes mellitus receive hormone replacement therapy?.  Int J Clin Pract . 1997;  51 299-303
  PubMedGoogle Scholar
• 12 Knopp R H, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women.  Atherosclerosis . 1994;  110(suppl) S83-S91
  CrossrefPubMedGoogle Scholar
• 13 Palin S L, Kumar S, Sturdee D W, Barnett A H. Hormone replacement therapy for postmenopausal women with diabetes.  Diabetes Obes Metab . 2001;  3 187-193
  CrossrefPubMedGoogle Scholar
• 14 Feher M D, Isaacs A J. Is hormone replacement therapy prescribed for postmenopausal diabetic women?.  Br J Clin Pract . 1996;  50 431-432
  PubMedGoogle Scholar
• 15 Moorhead T, Hannaford P, Warskyj M. Prevalence and characteristics associated with use of hormone replacement therapy in Britain.  Br J Obstet Gynaecol . 1997;  104 290-297
  PubMedGoogle Scholar
• 16 Keating N L, Cleary P D, Rossi A S, Zaslavsky A M, Ayanian J Z. Use of hormone replacement therapy by postmenopausal women in the United States.  Ann Intern Med . 1999;  130 545-553
  PubMedGoogle Scholar
• 17 Kaplan R C, Heckbert S R, Weiss N S. Postmenopausal estrogens and risk of myocardial infarction in diabetic women.  Diabetes Care . 1998;  21 1117-1121
  PubMedGoogle Scholar
• 18 Chmouliovsky L, Habicht F, James R W, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women.  Maturitas . 1999;  32 147-153
  CrossrefPubMedGoogle Scholar
• 19 van Baal M W, Kooistra T, Stehouwer C D. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women.  Curr Med Chem . 2000;  7 499-517
  PubMedGoogle Scholar
• 20 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial.  JAMA . 1995;  273 199-208
  CrossrefPubMedGoogle Scholar
• 21 Kornhauser C, Malacara J M, Garay M E, Perez-Luque E L. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension.  J Hum Hypertens . 1997;  11 405-411
  CrossrefPubMedGoogle Scholar
• 22 van Ittersum J F, van Baal M W, Kenemans P. Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women.  Am J Hypertens . 1998;  11 1147-1152
  CrossrefPubMedGoogle Scholar
• 23 van Baal M W, Emeis J J, van der Mooren J M, Kessel H, Kenemans P, Stehouwer C D. Impaired procoagulant-anticoagulant balance during hormone replacement therapy?.  <~>A randomised, placebo-controlled 12-week study. Thromb Haemost . 2000;  83 29-34
  PubMedGoogle Scholar
• 24 Ridker P M, Hennekens C H, Rifai N, Buring J E, Manson J E. Hormone replacement therapy and increased plasma concentration of C-reactive protein.  Circulation . 1999;  100 713-716
  PubMedGoogle Scholar
• 25 Cushman M, Legault C, Barrett-Connor E. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study.  Circulation . 1999;  100 717-722
  CrossrefPubMedGoogle Scholar
• 26 Ridker P M, Buring J E, Shih J, Matias M, Hennekens C H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.  Circulation . 1998;  98 731-733
  CrossrefPubMedGoogle Scholar
• 27 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.  Circulation . 1998;  97 425-428
  CrossrefPubMedGoogle Scholar
• 28 Sattar N, Perera M, Small M, Lumsden M A. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.  Lancet . 1999;  354 487-488
  CrossrefPubMedGoogle Scholar
• 29 Cornu C, Mercier C, Ffrench P. Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial.  Maturitas . 2000;  37 95-104
  CrossrefPubMedGoogle Scholar
• 30 Lunt H, Brown L J. Self-reported changes in capillary glucose and insulin requirements during the menstrual cycle.  Diabet Med . 1996;  13 525-530
  CrossrefPubMedGoogle Scholar
• 31 Hjortland M C, McNamara P M, Kannel W B. Some atherogenic concomitants of menopause: the Framingham Study.  Am J Epidemiol . 1976;  103 304-311
  PubMedGoogle Scholar
• 32 Matthews K A, Meilahn E, Kuller L H, Kelsey S F, Caggiula A W, Wing R R. Menopause and risk factors for coronary heart disease.  N Engl J Med . 1989;  321 641-646
  CrossrefPubMedGoogle Scholar
• 33 Lindheim S R, Presser S C, Ditkoff E C, Vijod M A, Stanczyk F Z, Lobo R A. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin.  Fertil Steril . 1993;  60 664-667
  PubMedGoogle Scholar
• 34 Walton C, Godsland I F, Proudler A J, Wynn V, Stevenson J C. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women.  Eur J Clin Invest . 1993;  23 466-473
  CrossrefPubMedGoogle Scholar
• 35 Toth M J, Sites C K, Eltabbakh G H, Poehlman E T. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women.  Diabetes Care . 2000;  23 801-806
  PubMedGoogle Scholar
• 36 Andersson B, Mattsson L A, Hahn L. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab . 1997;  82 638-643
  CrossrefPubMedGoogle Scholar
• 37 Brussaard H E, Gevers Leuven A J, Frolich M, Kluft C, Krans H M. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.  Diabetologia . 1997;  40 843-849
  CrossrefPubMedGoogle Scholar
• 38 Owens D, Collins P B, Johnson A, Tomkin G H. Lipoproteins and low-dose estradiol replacement therapy in post-menopausal type 2 diabetic patients: the effect of addition of norethisterone acetate.  Diabet Med . 2000;  17 308-315
  CrossrefPubMedGoogle Scholar
• 39 Goldman J A, Ovadia J L. The effect of estrogen on intravenous glucose tolerance in women.  Am J Obstet Gynecol . 1969;  103 172-178
  PubMedGoogle Scholar
• 40 Thom M, Chakravarti S, Oram D H, Studd J W. Effect of hormone replacement therapy on glucose tolerance in postmenopausal women.  Br J Obstet Gynaecol . 1977;  84 776-783
  PubMedGoogle Scholar
• 41 Lilley S H, Spivey J M, Vadlamudi S, Otvos J, Cummings D M, Barakat H. Lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipemic obese women with controlled type 2 diabetes mellitus.  J Clin Pharmacol . 1998;  38 1107-1115
  PubMedGoogle Scholar
• 42 Samaras K, Hayward C S, Sullivan D, Kelly R P, Campbell L V. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study.  Diabetes Care . 1999;  22 1401-1407
  PubMedGoogle Scholar
• 43 Felmeden D C, Lip G Y. Hormone replacement therapy and hypertension.  Blood Press . 2000;  9 246-249
  CrossrefPubMedGoogle Scholar
• 44 Kannel W B. Oral contraceptive hypertension and thromboembolism.  Int J Gynaecol Obstet . 1978;  16 466-472
  PubMedGoogle Scholar
• 45 August P, Oparil S. Hypertension in women.  J Clin Endocrinol Metab . 1999;  84 1862-1866
  CrossrefPubMedGoogle Scholar
• 46 Amigoni S, Morelli P, Parazzini F, Chatenoud L. Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy.  Maturitas . 2000;  34 25-32
  CrossrefPubMedGoogle Scholar
• 47 Gilligan D M, Badar D M, Panza J A, Quyyumi A A, Cannon III O R. Acute vascular effects of estrogen in postmenopausal women.  Circulation . 1994;  90 786-791
  PubMedGoogle Scholar
• 48 Hayward C S, Samaras K, Campbell L, Kelly R P. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women.  Am J Hypertens . 2001;  14 699-703
  CrossrefPubMedGoogle Scholar
• 49 Knopp R H, Warth M R, Carrol C J. Lipid metabolism in pregnancy. I. Changes in lipoprotein triglyceride and cholesterol in normal pregnancy and the effects of diabetes mellitus.  J Reprod Med . 1973;  10 95-101
  PubMedGoogle Scholar
• 50 Knopp R H, Broyles F E, Cheung M, Moore K, Marcovina S, Chandler W L. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.  Contraception . 2001;  63 1-11
  CrossrefPubMedGoogle Scholar
• 51 Falco C, Tormo G, Estelles A. Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy.  Haematologica . 2001;  86 92-98
  PubMedGoogle Scholar
• 52 Morrisett J D. The role of lipoprotein(a) in atherosclerosis.  Curr Atheroscler Rep . 2000;  2 243-250
  PubMedGoogle Scholar
• 53 Robinson J C, Folsom A R, Nabulsi A A, Watson R, Brancati F L, Cai J. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?.  <~>The Atherosclerosis Risk in Communities Study Investigators. Diabetes Care . 1996;  19 480-485
  PubMedGoogle Scholar
• 54 Hoogerbrugge N. Hypertriglyceridemie door oestrogeengebruik.  Ned Tijdschr Geneeskd . 1997;  141 1225-1227
  PubMedGoogle Scholar
• 55 Manning P J, Allum A, Jones S, Sutherland W H, Williams S M. The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial.  Arch Intern Med . 2001;  161 1772-1776
  CrossrefPubMedGoogle Scholar
• 56 Perera M, Sattar N, Petrie J R. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.  J Clin Endocrinol Metab . 2001;  86 1140-1143
  CrossrefPubMedGoogle Scholar
• 57 Friday K E, Dong C, Fontenot R U. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes.  J Clin Endocrinol Metab . 2001;  86 48-52
  CrossrefPubMedGoogle Scholar
• 58 Manwaring P, Morfis L, Diamond T, Howes L G. The effects of hormone replacement therapy on plasma lipids in type II diabetes.  Maturitas . 2000;  34 239-247
  CrossrefPubMedGoogle Scholar
• 59 Dunaif A, Utian W H, Brandenburg S L. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: consensus opinion of The North American Menopause Society.  Menopause . 2000;  7 87-95
  PubMedGoogle Scholar
• 60 Andersson B. Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment.  Drugs Aging . 2000;  17 399-410
  PubMedGoogle Scholar